Clinical Trial

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2026-11 -> 2026-08 2026-06-23
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-02
Trial Details
NCT Number NCT06809595
Lead Sponsor Definium Therapeutics US, Inc.
Conditions Generalized Anxiety Disorder
Enrollment 245 participants
Start Date 2025-01-29
Primary Completion 2026-08 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-10